**UNITED
      STATES**


**SECURITIES
      AND EXCHANGE COMMISSION**


**Washington,
      D.C. 20549**








**FORM
      10** - **QSB**








[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
      1934


For
      the
      quarter ended December 31, 2005





[_]
      TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
      OF
      1934


For
      the
      transition period from ____ to _____





**INTERACTIVE
      THERAPEUTICS, INC.**


**(FORMERLY
      TABATHA I, INC.)**


(Name
      of
      small business in its charter)





Colorado
            0-31743
            84-1536517(State
                or other jurisdiction of incorporation)
            (Commission
                File Number)
            (IRS
                Employer Identification Number)1117
                Herkimer Street, Houston, Texas
            77008(Address
                of principal executive offices)
            (Zip
                Code)





Registrant’s
      telephone number, including area code: (713) 402-6717





Check
      whether the issuer (1) filed all reports required to be filed by Section 13
      or
      15(d) of the Securities Exchange Act during the past 12 months (or for such
      shorter period that the registrant was required to file such reports), and
      (2)
      has been subject to such filing requirements for the past 90 days.





Yes
      [X ]   No
      [__]





Indicate
      by check mark whether the registrant is a shell company (as defined in Rule
      12b-2 of the Exchange Act).





Yes
      [X ]   No
      [__]





Applicable
      only to issuers involved in bankruptcy proceedings during the past five
      years:





Check
      whether the issuer has filed all documents and reports required to be filed
      by
      Section 12, 13 or 15(d) of the Exchange Act after the distribution of securities
      under a plan confirmed by a court.





Yes
      [__ ]   No
      [__]





Applicable
      only to corporate issuers:





State
      the
      number of shares outstanding of each of the issuer's classes of common equity,
      as of the latest practicable date: 81,302,500 as of May 24, 2006.





Transitional
      Small Business Disclosure Format (Check one): Yes [__] No [X]








**INTERACTIVE
      THERAPEUTICS, INC.**


**(FORMERLY
      TABATHA I, INC.)**


**INDEX
      TO FORM 10-QSB**


**December
      31, 2005**





**Part
                I**
            **Financial
                Information**Item
                1.
            Financial
                StatementsConsolidated
                Balance Sheets December 31, 2005 (unaudited) and
                March 31, 2005
            3Consolidated
                Statements of Operations (unaudited) Three
                and Nine Months Ended December 31, 2005 andInception
                (February 15, 2005) through
                December 31, 2005
            4Consolidated
                Statements of Cash Flows (unaudited) Nine
                Months Ended December 31, 2005 andInception
                (February 15, 2005) through
                December 31, 2005
            5Notes
                to Unaudited Consolidated Financial
                Statements
            6Item
                2.
            Management’s
                Discussion and Analysis of Results of Operations
                and Financial Condition
            8Item
                3.
            Controls
                and Procedures
            10**Part
                II**
            **Other
                Information**Item
                1.
            Legal
                Proceedings
            12Item
                2.
            Unregistered
                Sales of Equity Securities and Use of
                Proceeds
            12Item
                3.
            Defaults
                Upon Senior Securities
            12Item
                4.
            Submission
                of Matters to a Vote of Security
                Holders
            12Item
                5.
            Other
                Information
            12Item
                6.
            Exhibits
            13





2


**PART
      I. FINANCIAL INFORMATION**





**ITEM
      1.****FINANCIAL
      STATEMENTS**





**INTERACTIVE
      THERAPEUTICS, INC.**


**AND
      SUBSIDIARY**


**CONSOLIDATED
      BALANCE SHEETS**


**(A
      Developmental Stage Company)**


**(Formerly
      Tabatha I, Inc.)**





December
                31,
            
            March
                31,2005
            
            2005(Unaudited)**ASSETS**Current
                assets:Cash and cash equivalents
            
            $
            1,000
            
            $
            --Total
                assets
            
            $
            1,000
            
            $
            --**LIABILITIES
                AND SHAREHOLDERS' DEFICIT**Current
                liabilities:Accounts payable
            
            $
            18,107
            
            $
            1,792Accrued liabilities
            
            
            8,000
            
            
            --Total current liabilities
            
            
            26,107
            
            
            1,792Comittments
              and contingencies
            
            
            --
            
            
            --Shareholders'
                deficit:Preferred stock, no par value, 10,000,000 shares authorized, no
                shares issued or outstanding
            
            
            --
            
            
            --Common stock, no par value, 500,000,000 shares authorized, 81,302,500
                issued and outstanding at December 31 andMarch 31, 2005
            
            
            1,000
            
            
            1,000Stock subscription receivable
            
            
            --
            
            
            (1,000
            )Deficit accumulated in the developmental stage
            
            
            (26,107
            )
            
            (1,792
            )Total shareholders’ deficit
            
            
            (25,107
            )
            
            (1,792
            )Total
                liabilities and shareholders' deficit
            
            $
            1,000
            
            $
            --





See
      accompanying notes to unaudited consolidated financial
      statements.


3


**INTERACTIVE
      THERAPEUTICS, INC.**


**AND
      SUBSIDIARY**


**CONSOLIDATED
      STATEMENTS OF OPERATIONS**


**THREE
      AND NINE MONTHS ENDED DECEMBER 31, 2005 AND**


**INCEPTION
      (FEBRUARY 15, 2005) TO DECEMBER 31, 2005**


**(A
      Developmental Stage Company)**


**(Formerly
      Tabatha I, Inc.)**


**(Unaudited)**





Three
                Months
            
            Nine
                Months
            
            InceptionEnded
            
            Ended
            
            (February
                15, 2005) toDecember
                31, 2005
            
            December
                31, 2005
            
            December
                31, 2005General
                and administrative expenses
            
            $
            14,291
            
            $
            24,315
            
            $
            26,107Net loss
            
            $
            (14,291
            )
            $
            (24,315
            )
            $
            (26,107
            )Net
                loss per share:Basic and diluted
            
            $
            --
            
            $
            --Weighted
                average number of common shares outstanding:Basic and diluted
            
            
            81,302,500
            
            
            81,302,500








See
      accompanying notes to unaudited consolidated financial statements.





4


**INTERACTIVE
      THERAPEUTICS, INC.**


**AND
      SUBSIDIARY**


**CONSOLIDATED
      STATEMENTS OF CASH FLOWS**


**NINE
      MONTHS ENDED DECEMBER 31, 2005 AND**


**INCEPTION
      (** **FEBRUARY
      15, 2005) TO DECEMBER 31, 2005**


**(A
      Developmental Stage Company)**


**(Formerly
      Tabatha I, Inc.)**


**(Unaudited)**





Nine
                Months
            
            InceptionEnded
            
            (February
                15, 2005)December
                31, 2005
            
            to
                December 31, 2005Cash
                flows from operating activities:Net loss
            
            $
            (24,315
            )
            $
            (26,107
            )Adjustments to reconcile net loss to cash used in operating
                activities:Changes in assets and liabilities:Accounts payable and accrued liabilities
            
            
            24,315
            
            
            26,107Net
                cash used in operating activities
            
            
            --
            
            
            --Cash
                flows from investing activities
            
            
            --
            
            
            --Cash
                flows from financing activities:Collection of stock subscription receivable
            
            
            1,000
            
            
            1,000Net
                cash provided by financing activities
            
            
            1,000
            
            
            1,000Net
                increase in cash
            
            
            1,000
            
            
            1,000Cash
                and cash equivalents, beginning of period
            
            
            --
            
            
            --Cash
                and cash equivalents, end of period
            
            $
            1,000
            
            $
            1,000








Supplemental
                cash flow information:Interest paid
            
            $
            --
            
            $
            --Taxes paid
            
            $
            --
            
            $
            --





See
      accompanying notes to unaudited consolidated financial
      statements.


5


**INTERACTIVE
      THERAPEUTICS, INC.**


**AND
      SUBSIDIARY**


**(A
      DEVELOPMENTAL STAGE COMPANY)**


**(Formerly
      Tabatha I, Inc.)**


**NOTES
      TO CONSOLIDATED FINANCIAL STATEMENTS**


**DECEMBER
      31, 2005**


**(Unaudited)**





Note
      1.  Basis
      of
      Presentation





The
      accompanying unaudited consolidated financial statements of Interactive
      Therapeutics, Inc. have been prepared in accordance with generally accepted
      accounting principles for interim financial information and with the
      instructions to Form 10-QSB and Item 310 (b) of Regulation S-B. Accordingly,
      they do not include all of the information and footnotes required by generally
      accepted accounting principles for complete financial statements. In the opinion
      of Interactive Therapeutics, Inc., all adjustments (consisting of normal
      recurring accruals) considered necessary for a fair presentation have been
      included. Operating results for the three and nine month periods ended December
      31, 2005, are not necessarily indicative of the results that may be expected
      for
      the year ending March 31, 2006. For further information, refer to the
      consolidated financial statements and footnotes thereto included in the Annual
      Report on Form 10-KSB for the fiscal year ended March 31, 2005.





Note
      2.  Organization
      and Nature of Business





Interactive
      Therapeutics, Inc., (formerly Tabatha I, Inc.) a company in the developmental
      stage (the “Company” or “Interactive”), was originally incorporated on March 17,
      2000, in the State of Colorado. The Company is a small business issuer that
      has
      not conducted business operations nor had revenues from operations in each
      of
      its last two fiscal years. The Company is a "blank check" or "shell" company
      whose business plan was to seek, investigate, and, if warranted, acquire one
      or
      more properties or businesses, and to pursue other related activities intended
      to enhance shareholder value. The acquisition of a business opportunity may
      be
      made by purchase, merger, exchange of stock, or otherwise, and may encompass
      assets or a business entity, such as a corporation, joint venture, or
      partnership. The Company has no capital, and it is unlikely that it will be
      able
      to take advantage of more than one such business opportunity.




On
      February 25, 2005, the Company closed on a transaction acquiring all of the
      common stock of Zigen, Inc., a Texas corporation (“Zigen”), pursuant to an
      exchange agreement by and among the Company, Zigen and the stockholders of
      Zigen
      (the “Exchange Agreement”). As a result of the Exchange Agreement, Zigen became
      a wholly-owned subsidiary of the Company. Zigen is the continuing entity for
      accounting purposes.  Zigen was incorporated in the State of Texas on
      February 15, 2005. References herein to the Company include Zigen.




As
      a
      result of the closing of the Exchange Agreement, the Company issued an aggregate
      of 73,000,000 shares of its common stock to the former shareholders of Zigen
      (in
      exchange for all the outstanding capital stock of Zigen), resulting in the
      former shareholders of Zigen owning approximately 89.8% of the issued and
      outstanding Company common stock. The Company issued 66,430,000 shares of its
      common stock to Silver Star Holdings Trust of which Kevan Casey is Trustee
      and
      6,570,000 shares of its common stock to Carl A. Chase, the former shareholders
      of Zigen. Additionally, Kevan Casey was appointed as chairman and a director
      and
      J. Leonard Ivins was appointed to serve as chief executive officer, principal
      accounting officer and a director. Effective September 13, 2005, Mr. Casey
      resigned as a member of the board of directors and officer to devote attention
      to his commitments with his other business interests and Bradley Serres was
      appointed to serve as a director. Mr. Serres will be issued 100,000 shares
      of
      the Company’s restricted common stock for his one year tenure as a director,
      which the Company has valued at $24,000.





Effective
      July 25, 2005, the Company changed its name to Interactive Therapeutics, Inc.
      to
      more accurately reflect the business it intends to enter subsequent to the
      merger with Zigen and will focus its efforts for growth in the area of
      biotechnology.





6




Note
      3.  Significant Accounting Policies





*Principles
      of Consolidation*





The
      consolidated financial statements include the accounts of the Company and its
      wholly-owned subsidiary. All significant intercompany transactions and account
      balances have been eliminated.





*Stock
      Options*





On
      May
      25, 2005, the Board of Directors adopted the 2005 Stock Option Plan (the “2005
      Plan”), which allows for the issuance of up to 6,000,000 stock options to
      directors, executive officers, employees and consultants of the Company who
      are
      contributing to the Company’s success. On June 23, 2005, the Board of Directors
      increased the number of stock options for issuance under the 2005 Plan to
      8,000,000. The 2005 Plan was approved by the shareholders of the Company on
      July
      22, 2005. As of December 31, 2005, there were no stock options outstanding
      pursuant to the 2005 Plan.





During
      December 2002, the FASB issued SFAS No. 148. Statement 148 establishes standards
      for two alternative methods of transition to the fair value method of accounting
      for stock-based employee compensation of FASB SFAS No. 123 “Accounting for
      Stock-Based Compensation” (“SFAS 123”). SFAS 148 also amends and augments the
      disclosure provisions of SFAS 123 and Accounting Principles Board Opinion 28
      "Interim Financial Reporting" to require disclosure in the summary of
      significant accounting policies for all companies of the effects of an entity’s
      accounting policy with respect to stock-based employee compensation on reported
      net income and earnings per share in annual and interim financial statements.
      The transition standards and disclosure requirements of SFAS 148 are effective
      for fiscal years and interim periods ending after December 15, 2002. The Company
      has adopted only the disclosure provisions of this statement. The Company
      accounts for non-employee stock option expense in accordance with SFAS 123
      and
      EITF 96-18.





*Recently
      Issued Accounting Standards*





In
      December 2004, the Financial Accounting Standards Board, or FASB, issued
      Statement of Financial Accounting Standards No. 123R “Share-Based Payment” (SFAS
      123R). This statement revises SFAS No. 123, supersedes APB No. 25, and requires
      companies to recognize the cost of employee stock options and other awards
      of
      stock-based compensation based on the fair value of the award as of the grant
      date. The effective date of this pronouncement is as of the beginning of the
      first interim or annual period that begins after December 15, 2005. The Company
      is evaluating whether the adoption of FASB No. 123R will have a material effect
      on the Company’s consolidated financial position, results of operations or cash
      flows and will implement SFAS 123R effective April 1, 2006.




The
        FASB
        issued SFAS No. 155, *Accounting
        for Certain Hybrid Financial Instruments - an amendment of FASB Statements
        No.
        133 and 140,* in
        February 2006. SFAS No. 155 addresses accounting for beneficial interests
        in
        securitized financial instruments. The guidance allows fair value remeasurement
        for any hybrid financial instrument containing an embedded derivative that
        would
        otherwise require bifurcation and clarifies which interest-only and
        principal-only strips are not subject to SFAS No. 133. SFAS No. 155 also
        established a requirement to evaluate interests in securitized financial
        assets
        to identify any interests that are either freestanding derivatives or contain
        an
        embedded derivative requiring bifurcation. The statement is effective for
        all
        financial instruments issued or acquired after the beginning of the first
        fiscal
        year that begins after September 15, 2006. Management does not expect this
        statement will have a material impact on the Company’s financial position,
        results of operations or cash flows.





Note
      4.  Common
      Stock





Zigen
      issued 1,000 shares of common stock to its founding stockholders in exchange
      for
      $1,000 in cash. On February 25, 2005, the founding stockholders exchanged 100%
      of their common stock for approximately 89.8% of the Company as discussed in
      Note 1.





7


**ITEM
      2.****MANAGEMENT’S
      DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL
      CONDITION**





*The
      following discussion and analysis of the Company’s financial condition as of
      December 31, 2005, and its results of operations for the three and nine month
      periods ended December 31, 2005, should be read in conjunction with the audited
      consolidated financial statements and notes included in the Company’s Form
      10-KSB for the year ended March 31, 2005, filed with the Securities and Exchange
      Commission.*





**Forward-Looking
      Statements**





Some
      of
      the statements contained in this report discuss future expectations, contain
      projections of results of operations or financial condition, or state other
      "forward-looking" information. The words "believe," "intend," "plan," "expect,"
      "anticipate," "estimate," "project," "goal" and similar expressions identify
      such statement was made. These statements are subject to known and unknown
      risks, uncertainties, and other factors that could cause the actual results
      to
      differ materially from those contemplated by the statements. The forward-looking
      information is based on various factors and is derived using numerous
      assumptions. Factors that might cause or contribute to such a discrepancy
      include, but are not limited to the risks discussed in the Company’s other SEC
      filings. The Company does not promise to update forward-looking information
      to
      reflect actual results or changes in assumptions or other factors that could
      affect those statements. Future events and actual results could differ
      materially from those expressed in, contemplated by, or underlying such
      forward-looking statements.





**Overview**





Interactive
      is a developmental stage biopharmaceutical company with a primary focus on
      developing products to treat cancer, infectious diseases and other medical
      conditions associated with compromised immune systems. As a developmental stage
      company, substantially all efforts of the Company will be devoted to performing
      research and experimentation, conducting clinical trials, developing and
      acquiring intellectual properties, raising capital and recruiting and training
      personnel.





*Overview
      of Cancer and Treatment Methods*





Cancer
      is
      the second leading cause of death in the United States, exceeded only by heart
      disease. It is a devastating disease with tremendous unmet medical needs. The
      American Cancer Society estimated that 1.4 million new cases of cancer will
      be
      diagnosed in 2004 in the United States and 563,700 Americans are expected to
      die
      from cancer in 2004.





Cancer
      is
      a group of diseases characterized by uncontrolled cell division resulting in
      the
      development of a mass of cells, commonly known as a tumor, as well as the
      invasion and spreading of these cells. Cancerous tumors can arise in any tissue
      or organ within the human body. Cancer is believed to occur as a result of
      a
      number of factors, such as genetic predisposition, chemical agents, viruses
      and
      irradiation. These factors result in genetic changes affecting the ability
      of
      cells to regulate their growth and differentiation normally. When a normal
      cell
      becomes cancerous, it can spread to various sites in the body.





The
      most
      common methods of treating patients with cancer are surgery, radiation and
      drug
      therapy. A cancer patient often receives treatment with a combination of
      methods. Surgery and radiation therapy are particularly effective in patients
      where the disease is localized and has not spread to other tissues or organs.
      The most common method of treating patients with cancer that has spread beyond
      the primary site is to administer anticancer drugs by mouth or intravenously.
      In
      general, drugs used to treat cancer are classified as chemotherapy. Chemotherapy
      seeks to damage and kill cancer cells or to interfere with the molecular and
      cellular processes that control the development, growth and survival of
      malignant tumor cells. In many cases, chemotherapy consists of the
      administration of several different drugs in combination. Chemotherapy can
      cause
      patient weakness, loss of appetite, nausea and vomiting, and damage to various
      organs that can result in loss of normal body functions. Current treatment
      for
      most kinds of cancer is inadequate. Therefore, a significant need exists for
      new
      therapies which are more effective and/or have reduced side
      effects.





8




**Recent
      Developments**





Interactive
      Therapeutics, Inc. (formerly Tabatha I, Inc.) (the “Company” or “Interactive”)
      is a small business issuer that has not conducted business operations nor had
      revenues from operations in each of its last two fiscal years. It remains in
      the
      developmental stage and its business plan is to seek, investigate, and, if
      warranted, acquire one or more properties or businesses, and to pursue other
      related activities intended to enhance shareholder value. The acquisition of
      a
      business opportunity may be made by purchase, merger, exchange of stock, or
      otherwise, and may encompass assets or a business entity, such as a corporation,
      joint venture, or partnership. The Company has very limited capital, and it
      is
      unlikely that it will be able to take advantage of more than one such business
      opportunity. The Company cannot predict to what extent its liquidity and capital
      resources will be diminished prior to the consummation of a business combination
      or whether its capital will be further depleted by the operating losses (if
      any)
      of the business entity which it may eventually acquire.




On
      February 25, 2005, Interactive closed on a transaction acquiring all of the
      common stock of Zigen, Inc., a Texas corporation (“Zigen”), pursuant to an
      exchange agreement by and among the Company, Zigen and the stockholders of
      Zigen
      (the “Exchange Agreement”). As a result of the Exchange Agreement, Zigen became
      a wholly-owned subsidiary of the Company. Zigen was incorporated in the State
      of
      Texas on February 15, 2005. References herein to the Company include
      Zigen.




As
      a
      result of the closing of the Exchange Agreement, the Company issued an aggregate
      of 73,000,000 shares of its common stock to the former shareholders of Zigen
      (in
      exchange for all the outstanding capital stock of Zigen), resulting in the
      former shareholders of Zigen owning approximately 89.8% of the issued and
      outstanding Company common stock. The Company issued 66,430,000 shares of its
      common stock to Silver Star Holdings Trust of which Kevan Casey is Trustee
      and
      6,570,000 shares of its common stock to Carl A. Chase, the former shareholders
      of Zigen. Additionally, Kevan Casey was appointed as chairman and a director
      and
      J. Leonard Ivins was appointed to serve as chief executive officer, principal
      accounting officer and director. Effective September 13, 2005, Mr. Casey
      resigned as a member of the board of directors and officer to devote attention
      to his commitments with his other business interests and Bradley Serres was
      appointed to serve as a director. Mr. Serres will be issued 100,000 shares
      of
      the Company’s restricted common stock for his one year tenure as a director,
      which the Company has valued at $24,000.





Effective
      July 25, 2005, the Company changed its name to Interactive Therapeutics, Inc.
      to
      more accurately reflect the business it intends to enter subsequent to the
      merger with Zigen and will focus its efforts for growth in the area of
      biotechnology.








**Critical
      Accounting Policies**





*General*





The
      Consolidated Financial Statements and Notes to Consolidated Financial Statements
      contain information that is pertinent to this management’s discussion and
      analysis. The preparation of financial statements in conformity with accounting
      principles generally accepted in the United States of America requires
      management to make estimates and assumptions that affect the reported amounts
      of
      assets and liabilities and disclosure of any contingent assets and liabilities.
      Management believes these accounting policies involve judgment due to the
      sensitivity of the methods, assumptions and estimates necessary in determining
      the related asset and liability amounts. Management believes it has exercised
      proper judgment in determining these estimates based on the facts and
      circumstances available to its management at the time the estimates were made.
      The significant accounting policies are described in the Company's audited
      financial statements included in its annual report on Form 10-KSB for the year
      ended March 31, 2005 (See Note 2 in Notes to Consolidated Financial
      Statements).





9




**Results
      of Operations and Financial Condition**





Prior
      to
      the acquisition of Zigen, Interactive was a developmental stage company whose
      business plan was to seek, investigate, and, if warranted, acquire one or more
      properties or businesses, and to pursue other related activities intended to
      enhance shareholder value. The acquisition of a business opportunity may be
      made
      by purchase, merger, exchange of stock, or otherwise, and may encompass assets
      or a business entity, such as a corporation, joint venture, or partnership.
      The
      Company has no capital, and it is unlikely that it will be able to take
      advantage of more than one such business opportunity. The Company intends to
      seek opportunities demonstrating the potential of long-term growth as opposed
      to
      short-term earnings. During the nine months ended December 31, 2005, the Company
      incurred expenses of $24,315, which expenses are comprised primarily of legal,
      accounting and director’s fees.





**Liquidity
      and Capital Resources**





The
      Company has significant liquidity problems and has no meaningful capital
      resources or stockholder's equity. It may not be able to satisfy its estimated
      cash requirements for the next twelve months. In the event additional cash
      is
      required, the Company may have to borrow funds from stockholders or other
      sources, or seek funds from a private placement among new investors, none of
      which can be assured. The Company has faced this situation since inception
      and
      has managed to carry on and there is no reason to believe that it can not do
      so
      in the future. The Company cannot predict to what extent its lack of liquidity
      and capital resources will impair the consummation of a business combination
      or
      whether it will incur further operating losses through any business entity
      which
      it may eventually acquire. The Company has had no material business operations
      since 2000 and has never had any revenue. During these periods it has engaged
      in
      no significant operations other than organizational activities, acquisition
      of
      capital, and meeting its reporting obligations under the Securities Exchange
      Act
      of 1934, as amended. No revenues were received during this period. The Company
      anticipates that until a business combination is completed with an acquisition
      candidate, it will not generate revenue and may operate at a loss after
      completing a business combination, depending upon the performance of the
      acquired business.





**Off-Balance
      Sheet Arrangements**





The
      Company does not have any off-balance sheet arrangements.





**New
      Accounting Pronouncements**





In
      December 2004, the Financial Accounting Standards Board, or FASB, issued
      Statement of Financial Accounting Standards No. 123R “Share-Based Payment” (SFAS
      123R). This statement revises SFAS No. 123, supersedes APB No. 25, and requires
      companies to recognize the cost of employee stock options and other awards
      of
      stock-based compensation based on the fair value of the award as of the grant
      date. The effective date of this pronouncement is as of the beginning of the
      first interim or annual period that begins after December 15, 2005. The Company
      is evaluating whether the adoption of FASB No. 123R will have a material effect
      on the Company’s consolidated financial position, results of operations or cash
      flows and will implement SFAS 123R effective April 1, 2006.




The
      FASB
      issued SFAS No. 155, *Accounting
      for Certain Hybrid Financial Instruments - an amendment of FASB Statements
      No.
      133 and 140,* in
      February 2006. SFAS No. 155 addresses accounting for beneficial interests in
      securitized financial instruments. The guidance allows fair value remeasurement
      for any hybrid financial instrument containing an embedded derivative that
      would
      otherwise require bifurcation and clarifies which interest-only and
      principal-only strips are not subject to SFAS No. 133. SFAS No. 155 also
      established a requirement to evaluate interests in securitized financial assets
      to identify any interests that are either freestanding derivatives or contain
      an
      embedded derivative requiring bifurcation. The statement is effective for all
      financial instruments issued or acquired after the beginning of the first fiscal
      year that begins after September 15, 2006. Management does not expect this
      statement will have a material impact on the Company’s financial position,
      results of operations or cash flows.





10




**ITEM
      3.****CONTROLS
      AND PROCEDURES**





The
      Company maintains disclosure controls and procedures that are designed to ensure
      that information required to be disclosed in the Company’s reports pursuant to
      the Securities Exchange Act of 1934, as amended, is recorded, processed,
      summarized and reported within the time periods specified in the SEC’s rules and
      forms, and that such information is accumulated and communicated to the
      Company’s management, including its Chief Executive Officer and Chief Financial
      Officer, as appropriate, to allow timely decisions regarding required
      disclosure. In designing and evaluating the disclosure controls and procedures,
      the Company’s management recognized that any controls and procedures, no matter
      how well designed and operated, can provide only reasonable assurance of
      achieving the desired control objectives, and management necessarily was
      required to apply its judgment in evaluating the cost-benefit relationship
      of
      possible controls and procedures.





The
      nature of the business and the size of the Company have prevented the Company
      from being able to employ sufficient resources to enable it to have adequate
      segregation of duties within its internal control system. This condition is
      considered a reportable condition and has been discussed with the Board of
      Directors. The Company will continue to monitor and assess the costs and
      benefits of additional staffing in the accounting area.


11


**PART
      II OTHER INFORMATION**





**ITEM
      1.****LEGAL
      PROCEEDINGS**





None.





**ITEM
      2.****UNREGISTERED
      SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**





**Recent
      Sales of Unregistered Securities**





There
      were no sales of unregistered securities made by the Company during the quarter
      ended December 31, 2005.





**ITEM
      3.****DEFAULTS
      UPON SENIOR SECURITIES**





None.





**ITEM
      4.****SUBMISSION
      OF MATTERS TO A VOTE OF SECURITY HOLDERS**





None.





**ITEM
      5.****OTHER
      INFORMATION**





None.


12


**ITEM
      6.****EXHIBITS**





Exhibit
                No.
            Description3.1
            Articles
                of Incorporation (incorporated by reference to Exhibit 3.1 from
                Registration Statement on Form-SB filed with the Securities and Exchange
                Commission on October 11, 2000)3.2
            Amended
                Articles of Incorporation (incorporated by reference to Exhibit 3.2
                to
                Registrant’s Form 10-QSB filed with the Securities and Exchange Commission
                on November 21, 2005)3.3
            Bylaws
                of Tabatha I, Inc. (incorporated by reference to Exhibit 3.2 from
                Registration Statement on Form-SB filed with the Securities and Exchange
                Commission on October 11, 2000)4.1
            Specimen
                of Stock Certificate (incorporated by reference to Exhibit 4.1 from
                Registration Statement on Form-SB filed with the Securities and Exchange
                Commission on October 11, 2000)4.2
            Specimen
                Class A Convertible Preferred Stock Certificate (incorporated by
                reference
                to Exhibit 4.2 from Registration Statement on Form-SB filed with
                the
                Securities and Exchange Commission on October 11, 2000)14.1
            Code
                of Ethics (incorporated by reference to Exhibit 14.1 to Registrant’s Form
                10-KSB filed with the Securities and Exchange Commission June 29,
                2005)10.1
            Exchange
                Agreement between Tabatha I, Inc. and Zigen, Inc. dated February
                25, 2005
                (incorporated by reference to Exhibit 10.1 to Registrant’s Form 8-K filed
                with the Securities and Exchange Commission on May 31,
                2005)10.2
            2005
                Amended and Restated Stock Option (incorporated by reference to Exhibit
                A
                to Registrant’s Definitive Information Statement filed with the Securities
                and Exchange Commission on July 1, 2005)21.1
            List
                of Subsidiaries (incorporated by reference to Exhibit 21.1 to Registrant’s
                Form 10-QSB filed with the Securities and Exchange Commission on
                November
                21, 2005)31.1
            Certification
                pursuant to Rule 13a-14(a) or 15d-14(a)
                under the Securities Exchange Act of 1934, as amended (filed
                herewith)32.1
            Certification
                pursuant to 18 U.S.C. Section 1350, as
                adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
                (filed
                herewith)





13


**SIGNATURES**







Pursuant
      to the requirements of Section 13 or 15(d) of the Securities Exchange Act of
      1934, the Registrant has duly caused this report to be signed on its behalf
      by
      the undersigned, thereunto duly authorized:




**INTERACTIVE
      THERAPEUTICS, INC.**





By: /s/
      J.
      Leonard Ivins ___________


J.
      Leonard Ivins, Chief Executive Officer





Date:
      May
      25, 2006





Pursuant
      to the requirements of the Securities Exchange Act of 1934, this report has
      been
      signed below by the following persons on behalf of the Registrant and in the
      capacities and on the dates indicated.


**INTERACTIVE
                THERAPEUTICS, INC.**Date: May
                25,
                2006
              By:
              /s/ J.
                Leonard IvinsJ. Leonard IvinsCEO
                and
                Principal Accounting
                Officer